| Name | Title | Contact Details |
|---|---|---|
Lucas Donigian |
Vice President, Head of Business Development and Commercial | Profile |
Bijal Desai |
Vice President of Finance and Strategy | Profile |
Laura O`Connor |
Vice President of Human Resources and Diversity, Equity, and Inclusion | Profile |
Neil Klompas |
Chief Operating Officer and Chief Financial Officer | Profile |
Prem Girn |
Senior Director and Human Resources Business Partner | Profile |
Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve 2,000+ facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.
Portage is a unique entity in the world of biotechnology, catalyzing R&D to produce more quality clinical programs and maximize potential returns.
Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer:” the tumor blood vessels. Batu’s flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics plans to file an Investigational New Drug (IND) application for ValloVax in Q1 of 2015, seeking clinical approval to treat patients with lung cancer.
GenWay Biotech is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies.